Global Bronchodilators Market Report and Forecast 2025-2034

Global Bronchodilators Market Outlook

The bronchodilators market size was valued at USD 29.3 billion in 2024, driven by the rising incidence of chronic lung diseases like COPD and asthma across the globe. The market is expected to grow at a CAGR of 4.6% during the forecast period of 2025-2034, with the values likely to rise from USD 30.6 billion in 2025 to USD 43.9 billion by 2034.

Bronchodilators: Introduction

A bronchodilator is a medication that helps in the relaxation of the muscles around the bronchi, facilitating easy breathing. It is usually used to relieve the symptoms of asthma, COPD (chronic obstructive pulmonary disease) and other lung diseases. A bronchodilator helps clean the mucus from lungs, allowing it to move freely and get out of the body easily.

There are two forms, mainly short-acting bronchodilators that are effective for 3-6 hours while long-acting bronchodilators that provide help up to 12 hours. They are available as inhalers and nebulizers.

Bronchodilators Market Analysis

With the emergence of COVID-19, the bodies have become more susceptible to chronic respiratory illnesses. β2 adrenoceptor agonists bronchodilators have also found their application as an alternative treatment for treating COVID infected patients, as a result, bronchodilators market demand has seen an upswing in the historic period.

The incidence of chronic lung diseases has led to an increased demand for quality treatment for patients. Bronchodilators are still widely used to treat both COPD and asthma, hence, there have been several new advancements in the existing technology. A contemporary approach to formulate a new dual bronchodilator therapy is in the works. This drug class called MABA has both mAChR antagonism and β2-agonist activity in one molecule. It is believed to be better than the existing combinations due to its ‘triple therapy’ (treatment alternative for COPD) feature. The MABA Batefenterol is under an advanced clinical development stage.

Bronchodilator drugs are also used in combinations to treat lung diseases. For instance, AstraZenenca got the first and only asthma exacerbation risk reducing medication Airsupra (PT027) approved by the FDA in January 2023.It is the first ever drug that contains a combination of albuterol (β2 adrenergic agonist) and budesonide (corticosteroid). With increased application and demand, it is a clear indicator that bronchodilator market growth is certain in the upcoming years.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Bronchodilators Market Segmentation

Market Breakup by Drug Class

• Beta-Adrenergic Bronchodilators

• Xanthine Derivatives

• Anticholinergic Bronchodilators

• Others

Market Breakup by Indication

• Asthma

• Chronic Obstructive Pulmonary Disease (COPD)

• Allergic Reactions

• Breathing Problem

• Others

Market Breakup by Route of Administration

• Oral

• Parenteral

• Inhalational

• Others

Market Breakup by End User

• Hospitals

• Speciality Clinics

• Home Healthcare

• Others

Market Breakup by Region

• North America

• Europe

• Asia Pacific

• Latin America

• Middle East and Africa

Bronchodilators Market Overview

It is estimated that over 300 million asthma patients carry the burden of high morbidities and mortalities across the world. As a result, the bronchodilator market value has risen, with the vision to mitigate the number of morbidities associated with chronic respiratory diseases. The Asia Pacific region is expected to experience rapid growth in terms of market share owing to the presence of a geriatric population in the region. As a precautionary measure, the governments are more alert and working regularly by setting up several awareness campaigns.

The United States is anticipated to lead the bronchodilator market share, which is influenced by the existence of several healthcare leaders in the area. United States healthcare industry is always thriving to bring new innovations in the market. For instance, in a recent trial, Sanofi's Dupixent® showcased significant clinical potential to reduce COPD aggravations by 30%. This indicates that the country is set to experience the latest technological advances exclusively.

Bronchodilators Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

• Bayer AG

• Teva Pharmaceutical Industries Ltd. 

• Sun Pharmaceutical Industries Ltd. 

• Hikma Pharmaceutical PLC 

• Amneal Pharmaceuticals LLC 

• Aurobindo Pharma 

• Johnsons & Johnsons Services Pvt Ltd 

• GSK Plc 

• Thermo Fisher Scientific Inc. 

• Siemens 

• Cipla Inc. 

• AstraZeneca 

• Mylan N.V.

Key Highlights of the Report